Instil Bio Inc.

News & Events

Press Releases

In The Media

1. Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

   GlobeNewswire AUG 13, 2025 6:00 AM EDT
   With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (&#...
   READ ARTICLE

2. ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

   GlobeNewswire JUL 31, 2025 6:00 AM EDT
   Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamou...
   READ ARTICLE

3. Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

   GlobeNewswire JUL 2, 2025 6:00 AM EDT
   US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 ...
   READ ARTICLE

4. Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

   GlobeNewswire JUN 11, 2025 7:00 AM EDT
   DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL)...
   READ ARTICLE

5. Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

   GlobeNewswire JUN 2, 2025 7:00 AM EDT
   DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL)...
   READ ARTICLE

6. Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

   GlobeNewswire MAY 30, 2025 7:00 AM EDT
   DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-sta...
   READ ARTICLE

7. Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

   GlobeNewswire MAY 23, 2025 7:00 AM EDT
   DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") an...
   READ ARTICLE

8. Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

   GlobeNewswire MAY 22, 2025 6:00 AM EDT
   Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to...
   READ ARTICLE

9. Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

   GlobeNewswire MAY 13, 2025 7:00 AM EDT
   Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemothera...
   READ ARTICLE

10. Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    GlobeNewswire MAR 4, 2025 7:09 AM EST
    Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnc...
    READ ARTICLE